Literature DB >> 16352901

Drugs and social exclusion in ten European cities.

Joan Carles March1, Eugenia Oviedo-Joekes, Manuel Romero.   

Abstract

AIM: To describe social characteristics seen among socially excluded drug users in 10 cities from 9 European countries, and identify which social exclusion indicators (i.e. housing, employment, education) are most closely linked to intravenous drug use.
DESIGN: Cross-sectional survey.
SETTING: Interviews were held in social services centers, town halls, streets, squares and other usual meeting points of the target population. PARTICIPANTS: The sample comprises 1,879 participants who have used heroin and/or cocaine and certain derivatives (92.3%) over the last year. Males accounted for 69.7% of the sample, and the mean age was 30.19 years. Participants were recruited in 10 cities: Seville and Granada, Spain; Cologne, Germany; Vienna, Austria; Brussels, Belgium; Athens, Greece; Dublin, Ireland; London, England; Lisbon, Portugal, and Perugia, Italy. MEASUREMENTS: Structured face-to-face questionnaire, conducted by privileged access interviewers.
RESULTS: Cannabis, heroin and cocaine are the most widely used substances. In the total sample, 60.2% injected drugs during the last year, 45.9% reported having hepatitis C; 54.9% have been in prison; 14.2% are homeless; 11.3% have a regular job, and 35.2% are involved in illegal activities. Hierarchical logistic regression analysis (injectors and non-injectors) showed that older participants have a greater likelihood of injecting than younger ones. Social exclusion variables associated with intravenous drug use are incarceration, homelessness, irregular employment, and delinquency. Participants who abandoned or were expelled from a drug treatment program are at greater risk of injecting drugs than participants who have never had treatment, are currently in treatment or have been released.
CONCLUSION: Personal, social, and economic conditions are all linked in a process of social exclusion that compounds problem drug misuse. Given the findings of this study, we believe that there is a clear need for specific programs targeting specific groups, i.e., distinct strategies must be set in place, in line with the profile and needs of the patient in each context. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16352901     DOI: 10.1159/000088581

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  20 in total

1.  Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Catalina Lopez-Quintero; Deborah S Hasin; José Pérez de Los Cobos; Abigail Pines; Shuai Wang; Bridget F Grant; Carlos Blanco
Journal:  Addiction       Date:  2010-11-16       Impact factor: 6.526

2.  Employment Cessation, Long Term Labour Market Engagement and HIV Infection Risk Among People Who Inject Drugs in an Urban Canadian Setting.

Authors:  Lindsey Richardson; Mitchell Mammel; M-J Milloy; Kanna Hayashi
Journal:  AIDS Behav       Date:  2019-12

3.  Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997-2007.

Authors:  Giuliano Zamparutti; Fabrizio Schifano; John M Corkery; Adenekan Oyefeso; A Hamid Ghodse
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

4.  How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies.

Authors:  Joanne Neale; Caral Brown; Aimee N C Campbell; Jermaine D Jones; Verena E Metz; John Strang; Sandra D Comer
Journal:  Addiction       Date:  2018-12-28       Impact factor: 6.526

5.  Factors associated with employment among a cohort of injection drug users.

Authors:  Lindsey Richardson; Evan Wood; Kathy Li; Thomas Kerr
Journal:  Drug Alcohol Rev       Date:  2010-05

6.  The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; Suzanne Brissette; Jill Chettiar; Pascal Schneeberger; David C Marsh; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  J Urban Health       Date:  2008-08-29       Impact factor: 3.671

7.  Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; David C Marsh; Daphne Guh; Suzanne Brissette; Candice Gartry; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

8.  Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment.

Authors:  Kirsten Marchand; Eugenia Oviedo-Joekes; Daphne Guh; David C Marsh; Suzanne Brissette; Martin T Schechter
Journal:  Harm Reduct J       Date:  2012-01-25

9.  Policy makers ignoring science and scientists ignoring policy: the medical ethical challenges of heroin treatment.

Authors:  Dan Small; Ernest Drucker
Journal:  Harm Reduct J       Date:  2006-05-02

10.  NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America.

Authors:  Candice C Gartry; Eugenia Oviedo-Joekes; Nancy Laliberté; Martin T Schechter
Journal:  Harm Reduct J       Date:  2009-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.